NCT03652142 is a clinical trial of Biomarker Research in HNSCC, sponsored by Attikon Hospital.

Who is sponsoring NCT03652142?

NCT03652142 is sponsored by Attikon Hospital.

What drugs are being tested in NCT03652142?

Interventions in NCT03652142: Biomarker Research, Nivolumab.

What condition does NCT03652142 study?

NCT03652142 studies HNSCC, DNA Damage, DNA Double Strand Break.

Is NCT03652142 still recruiting?

NCT03652142 is currently status unknown. Last updated 29 August 2018.

Last reviewed 2018-08-29 · How we verify

NCT03652142

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma

Status unknown Last updated 29 August 2018

What this trial tests

trial testing Biomarker Research in HNSCC in 50 participants. Status unknown.

Timeline

1 May 2018

Primary endpoint
1 May 2020

1 May 2020

Quick facts

Lead sponsor	Attikon Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 May 2018
Primary completion	1 May 2020
Estimated completion	1 May 2020
Sites	1 location across Greece

Drugs / interventions tested

Biomarker Research
Nivolumab (nivolumab) — full drug profile →

Conditions studied

HNSCC — all drugs for HNSCC →
DNA Damage — all drugs for DNA Damage →
DNA Double Strand Break — all drugs for DNA Double Strand Break →

Sponsor

Attikon Hospital

Who can join

18 and older, any sex, with HNSCC or DNA Damage. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Nivolumab is FDA-approved for the treatment of patients with recurrent/metastatic Head and Neck Squamous Cell Carcinoma (HNSCC). HNSCC whose disease has progressed within 6 months after platinum-based chemotherapy. The development of predictive biomarkers is needed to optimize patient benefit, minimize risk of toxicities and guide combination strategies.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
Gavrielatou N, Fortis E, Spathis A, Anastasiou M, et al · · 2024 · cited 46× · PMID 38159908 · DOI 10.1016/j.annonc.2023.12.011
Tumor and blood B-cell abundance outperforms established immune checkpoint blockade response prediction signatures in head and neck cancer.
Chang TG, Spathis A, Schäffer AA, Gavrielatou N, et al · · 2025 · cited 15× · PMID 39551185 · DOI 10.1016/j.annonc.2024.11.008
Association of DNA damage response signals and oxidative stress status with nivolumab efficacy in patients with Head and Neck Squamous Cell Carcinoma.
Papanikolaou C, Economopoulou P, Spathis A, Kotsantis I, et al · · 2025 · cited 4× · PMID 40410274 · DOI 10.1038/s41416-025-03032-2
UVC-Induced Oxidative Stress and DNA Damage Repair Status in Head and Neck Squamous Cell Carcinoma Patients with Different Responses to Nivolumab Therapy.
Papanikolaou C, Economopoulou P, Gavrielatou N, Mavroeidi D, et al · · 2025 · cited 2× · PMID 40001963 · DOI 10.3390/biology14020195

Verify or expand the search:

Other trials of Biomarker Research

Trials testing the same drug.

NCT02160366 — Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients · unknown

Other recruiting trials for HNSCC

Currently open trials in the same condition.

NCT07035249 — DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07081984 — Study of TI-0093 Injection With Recurrent/Metastatic HPV-16 Positive Solid Tumors · Phase 1 · recruiting
NCT07182149 — A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors · Phase 1 · recruiting
NCT07106827 — A Study of GV20-0251 in Advanced or Refractory Solid Tumors · Phase 1 · recruiting
NCT07136545 — A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metas · Phase 1, PHASE2 · recruiting

Other Attikon Hospital trials

Trials by the same sponsor.

NCT07425457 — Cryoneurolysis Prior to Total Knee Arthroplasty (CRYO-TKA Trial) · NA · recruiting
NCT06646107 — Adherence to Mediterranean Diet in Type 1 Diabetes Initiating Minimed 780G: Glucose Metrics vs Insulin Metrics, is There · recruiting
NCT06810700 — The Association Between Time in Range With Markers of Endothelial and Cardiovascular Function · not yet recruiting
NCT06978387 — The Association Between Glycemic Metrics and Cardiovascular Markers in Patients With Type 1 Diabetes. · active not recruiting
NCT06749613 — Digestive Enzyme Formulation Intervention in IBS Patients Who Previously Clinically Responded to Mediterranean LFD · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03652142 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Attikon Hospital
Last refreshed: 29 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03652142.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing